| abstract |
The invention belongs to the field of medicinal chemistry and provides a 3-hydroxy-3-methylglutarphthalein coenzyme A reductase inhibitor, which is a 3-fluoro-caprolactone fragment and formed after the lactone is opened. 1-Fluoro-3-hydroxyvaleric acid and its salts or esters are multi-substituted pyrimidine statin fluorine-containing modifications, and its structural formula is described as follows: These compounds have been tested to have the effect of inhibiting the activity of HMG-coA reductase, and can be used as a new generation of potential HMG-CoA reductase inhibitors. |